SG11201807074VA - Novel pyrrolidine derivatives - Google Patents
Novel pyrrolidine derivativesInfo
- Publication number
- SG11201807074VA SG11201807074VA SG11201807074VA SG11201807074VA SG11201807074VA SG 11201807074V A SG11201807074V A SG 11201807074VA SG 11201807074V A SG11201807074V A SG 11201807074VA SG 11201807074V A SG11201807074V A SG 11201807074VA SG 11201807074V A SG11201807074V A SG 11201807074VA
- Authority
- SG
- Singapore
- Prior art keywords
- co7d
- grenzacherstrasse
- basel
- roche
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
Title: NOVEL PYRROLIDINE DERIVATIVES F (I) W O 20 17 / 144483 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/144483 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: CO7D 403/12 (2006.01) CO7D 401/12 (2006.01) A61K 31/4025 (2006.01) CO7D 403/14 (2006.01) A61K 31/41 (2006.01) CO7D 405/12 (2006.01) A61K 31/4155 (2006.01) CO7D 413/12 (2006.01) A61K 31/4192 (2006.01) CO7D 417/12 (2006.01) A61K 31/4196 (2006.01) CO7D 207/16 (2006.01) A61K 31/422 (2006.01) A61P 3/10 (2006.01) A61K 31/427 (2006.01) A61P 7/00 (2006.01) A61K 31/4439 (2006.01) A61P 7/02 (2006.01) A61K 31/506 (2006.01) (21) International Application Number: PCT/EP2017/053967 (22) International Filing Date: 22 February 2017 (22.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16157679.8 26 February 2016 (26.02.2016) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US). (72) Inventors: HAAP, Wolfgang; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). KUHN, Bernd; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). LUEBBERS, Thomas; c/o F. Hoff- mann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). PETERS, Jens-Uwe; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). (74) Agent: POMERANC, Didier; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, [Continued on next page] 11111111111111011101111111111101011111011101011111111111111111111011111111111110111111 (57) : The invention relates to a compound of for- mula (I) wherein R 1 and R 2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament against diabetes, atherosclerosis and other conditions linked to cathepsin. WO 2017/144483 All#110HOMOIDEIR0101301011101110HEIMODEVOIMIE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16157679 | 2016-02-26 | ||
| PCT/EP2017/053967 WO2017144483A1 (en) | 2016-02-26 | 2017-02-22 | Novel pyrrolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807074VA true SG11201807074VA (en) | 2018-09-27 |
Family
ID=55443159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807074VA SG11201807074VA (en) | 2016-02-26 | 2017-02-22 | Novel pyrrolidine derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10689339B2 (en) |
| EP (1) | EP3419970B1 (en) |
| JP (1) | JP6952044B2 (en) |
| KR (1) | KR20180111862A (en) |
| CN (1) | CN108699044B (en) |
| AR (1) | AR107717A1 (en) |
| AU (1) | AU2017224343B2 (en) |
| CA (1) | CA3011652C (en) |
| CL (1) | CL2018002347A1 (en) |
| CO (1) | CO2018007756A2 (en) |
| CR (1) | CR20180404A (en) |
| DK (1) | DK3419970T3 (en) |
| ES (1) | ES2775781T3 (en) |
| HR (1) | HRP20200307T1 (en) |
| HU (1) | HUE047842T2 (en) |
| IL (1) | IL260130B (en) |
| LT (1) | LT3419970T (en) |
| MA (1) | MA43667B1 (en) |
| MX (1) | MX2018009638A (en) |
| MY (1) | MY196560A (en) |
| PH (1) | PH12018501585B1 (en) |
| PL (1) | PL3419970T3 (en) |
| PT (1) | PT3419970T (en) |
| RS (1) | RS59938B1 (en) |
| RU (1) | RU2736498C1 (en) |
| SG (1) | SG11201807074VA (en) |
| SI (1) | SI3419970T1 (en) |
| TW (1) | TWI740903B (en) |
| UA (1) | UA122084C2 (en) |
| WO (1) | WO2017144483A1 (en) |
| ZA (1) | ZA201804120B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7001068B2 (en) | 2017-01-24 | 2022-01-19 | アステラス製薬株式会社 | Phenyldifluoromethyl substituted proline amide compound |
| TW202023542A (en) | 2018-09-18 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5518997B2 (en) * | 2009-04-20 | 2014-06-11 | エフ．ホフマン−ラ ロシュ アーゲー | Proline derivatives as cathepsin inhibitors |
| AU2012334123B2 (en) * | 2011-11-11 | 2016-12-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates |
| US8729061B2 (en) * | 2011-11-25 | 2014-05-20 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| US9427108B2 (en) * | 2011-12-09 | 2016-08-30 | W.C. Bradley Co. | Cooking grate with adjustable heating characteristics |
| US8802665B2 (en) * | 2012-02-17 | 2014-08-12 | Genentech, Inc. | Pyrrolidine derivatives |
| EA025166B1 (en) * | 2012-08-21 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Pyridine derivatives |
-
2017
- 2017-02-22 CR CR20180404A patent/CR20180404A/en unknown
- 2017-02-22 CN CN201780013397.XA patent/CN108699044B/en active Active
- 2017-02-22 RS RS20200183A patent/RS59938B1/en unknown
- 2017-02-22 SI SI201730195T patent/SI3419970T1/en unknown
- 2017-02-22 SG SG11201807074VA patent/SG11201807074VA/en unknown
- 2017-02-22 LT LTEP17705662.9T patent/LT3419970T/en unknown
- 2017-02-22 PT PT177056629T patent/PT3419970T/en unknown
- 2017-02-22 RU RU2018133640A patent/RU2736498C1/en active
- 2017-02-22 MA MA43667A patent/MA43667B1/en unknown
- 2017-02-22 EP EP17705662.9A patent/EP3419970B1/en active Active
- 2017-02-22 MY MYPI2018001465A patent/MY196560A/en unknown
- 2017-02-22 DK DK17705662.9T patent/DK3419970T3/en active
- 2017-02-22 UA UAA201809397A patent/UA122084C2/en unknown
- 2017-02-22 JP JP2018541661A patent/JP6952044B2/en active Active
- 2017-02-22 KR KR1020187024347A patent/KR20180111862A/en not_active Application Discontinuation
- 2017-02-22 MX MX2018009638A patent/MX2018009638A/en unknown
- 2017-02-22 WO PCT/EP2017/053967 patent/WO2017144483A1/en active Application Filing
- 2017-02-22 CA CA3011652A patent/CA3011652C/en active Active
- 2017-02-22 HU HUE17705662A patent/HUE047842T2/en unknown
- 2017-02-22 AU AU2017224343A patent/AU2017224343B2/en active Active
- 2017-02-22 PL PL17705662T patent/PL3419970T3/en unknown
- 2017-02-22 ES ES17705662T patent/ES2775781T3/en active Active
- 2017-02-24 TW TW106106388A patent/TWI740903B/en active
- 2017-02-24 AR ARP170100467A patent/AR107717A1/en unknown
-
2018
- 2018-06-19 IL IL260130A patent/IL260130B/en active IP Right Grant
- 2018-06-20 ZA ZA2018/04120A patent/ZA201804120B/en unknown
- 2018-07-25 PH PH12018501585A patent/PH12018501585B1/en unknown
- 2018-07-26 CO CONC2018/0007756A patent/CO2018007756A2/en unknown
- 2018-08-16 CL CL2018002347A patent/CL2018002347A1/en unknown
- 2018-08-24 US US16/111,721 patent/US10689339B2/en active Active
-
2020
- 2020-02-24 HR HRP20200307TT patent/HRP20200307T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909344SA (en) | Anti-lag3 antibodies | |
| SG11201804807VA (en) | Computer architecture and method for modifying data intake parameters based on a predictive model | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201408678WA (en) | Catalysts and methods for polyester production | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201408261UA (en) | Syringe | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804890TA (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose |